Selected article for: "effective treatment and infected people"
Author: Chen, Zhang-Ren; Zhou, Ying; Liu, Jin; Peng, Hong-Wei; Zhou, Jian; Zhong, Hai-Li; Liu, Li-Li; Lai, Ming-Fang; Wei, Xiao-Hua; Wen, Jin-Hua
Title: Pharmacotherapics Advice in Guidelines for COVID-19
  • Cord-id: 1n0o4akm
  • Document date: 2020_6_24
    • ID: 1n0o4akm
    Snippet: Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to
    Document: Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.

    Search related documents:
    Co phrase search for related documents
    • active metabolite and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • active metabolite and liver damage: 1
    • active metabolite and lopinavir ritonavir: 1
    • active rheumatoid arthritis and acute respiratory syndrome: 1, 2
    • acute ards respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir treatment ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome patient and lopinavir ritonavir: 1
    • acute respiratory syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver damage induce: 1
    • acute respiratory syndrome and lopinavir bioavailability: 1
    • acute respiratory syndrome and lopinavir interferon triple combination: 1
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir toxicity: 1, 2
    • acute respiratory syndrome and lopinavir treatment ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • liver damage and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver damage and lopinavir treatment ritonavir: 1, 2